{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:54:33Z","timestamp":1780458873701,"version":"3.54.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10741-021-10174-x","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T09:03:03Z","timestamp":1635411783000},"page":"1493-1503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["99mTechnetium-labeled cardiac scintigraphy for suspected amyloidosis: a review of current and future directions"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8303-9415","authenticated-orcid":false,"given":"Jean Michel","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-7999","authenticated-orcid":false,"given":"Ahmed Ibrahim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Pournazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-0484","authenticated-orcid":false,"given":"Mouaz H.","family":"Al-Mallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"10174_CR1","unstructured":"Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32(1):45\u201359. Accessed 16 Jun 2021"},{"key":"10174_CR2","doi-asserted-by":"publisher","unstructured":"Sipe JD, Benson MD, Buxbaum JN et al (2016) Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines. Amyloid 23(4):209\u2013213.\u00a0https:\/\/doi.org\/10.1080\/13506129.2016.1257986. Accessed 16 Jun 2021","DOI":"10.1080\/13506129.2016.1257986"},{"key":"10174_CR3","doi-asserted-by":"publisher","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS et al (2018) Amyloid nomenclature 2018: recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid 25(4):215\u2013219. https:\/\/doi.org\/10.1080\/13506129.2018.1549825. Accessed 16 Jun 2021","DOI":"10.1080\/13506129.2018.1549825"},{"key":"10174_CR4","doi-asserted-by":"publisher","unstructured":"Siddiqi OK, Ruberg FL (2018) Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med 28(1):10\u201321.\u00a0https:\/\/doi.org\/10.1016\/j.tcm.2017.07.004. Accessed 16 Jun 2021","DOI":"10.1016\/j.tcm.2017.07.004"},{"key":"10174_CR5","doi-asserted-by":"publisher","unstructured":"Muchtar E, Gertz MA, Kumar SK et al (2017) Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129(15):2111\u20132119.\u00a0https:\/\/doi.org\/10.1182\/blood-2016-11-751628. Accessed 16 Jun\u00a02021","DOI":"10.1182\/blood-2016-11-751628"},{"key":"10174_CR6","doi-asserted-by":"crossref","unstructured":"Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451-2466. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.075Accessed 6\u00a0Oct 2021","DOI":"10.1016\/j.jacc.2015.09.075"},{"key":"10174_CR7","doi-asserted-by":"publisher","unstructured":"Dorbala S, Ando Y, Bokhari S et al (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol\u00a026(6):2065\u20132123.\u00a0https:\/\/doi.org\/10.1007\/s12350-019-01760-6. Accessed 2 Jun 2021","DOI":"10.1007\/s12350-019-01760-6"},{"key":"10174_CR8","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404\u20132412.\u00a0https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612. Accessed 16 Jun\u00a02021","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"10174_CR9","doi-asserted-by":"publisher","unstructured":"Ali A, Turner DA, Rosenbush SW, Fordham EW (1981) Bone scintigram in cardiac amyloidosis: a case report. Clin Nucl Med\u00a06(3):105\u2013108.\u00a0https:\/\/doi.org\/10.1097\/00003072-198103000-00003. Accessed 28 Jun\u00a02021","DOI":"10.1097\/00003072-198103000-00003"},{"key":"10174_CR10","doi-asserted-by":"publisher","unstructured":"Schiff S, Bateman T, Moffatt R, Davidson R, Berman D (1982) Diagnostic considerations in cardiomyopathy: unique scintigraphic pattern of diffuse biventricular technetium-99m-pyrophosphate uptake in amyloid heart disease. Am Heart J 103(4 Pt 1):562\u2013563.\u00a0https:\/\/doi.org\/10.1016\/0002-8703(82)90343-x. Accessed 28 Jun\u00a02021\u00a0","DOI":"10.1016\/0002-8703(82)90343-x"},{"key":"10174_CR11","doi-asserted-by":"publisher","unstructured":"Sobol SM, Brown JM, Bunker SR, Patel J, Lull RJ (1982) Noninvasive diagnosis of cardiac amyloidosis by technetium-99m-pyrophosphate myocardial scintigraphy. Am Heart J\u00a0103(4 Pt 1):563\u2013566. https:\/\/doi.org\/10.1016\/0002-8703(82)90344-1. Accessed\u00a028 Jun\u00a02021","DOI":"10.1016\/0002-8703(82)90344-1"},{"key":"10174_CR12","doi-asserted-by":"publisher","unstructured":"Shih WJ, DeLand FH, Domstad PA, Stahr BJ, Powell RD, Yoneda K (1985) Scintigraphic findings in primary amyloidosis of the heart and stomach. Clin Nucl Med\u00a010(7):466\u2013467. https:\/\/doi.org\/10.1097\/00003072-198507000-00003. Accessed 28 Jun 2021","DOI":"10.1097\/00003072-198507000-00003"},{"key":"10174_CR13","unstructured":"Ptacin MJ, Bamrah V, Duthie E (1985) Technetium 99m-pyrophosphate scintigraphy in amyloid cardiomyopathy. Wis Med J 84:25\u201327"},{"key":"10174_CR14","doi-asserted-by":"publisher","unstructured":"Li CK, Rabinovitch MA, Juni JE et al (1985) Scintigraphic characterization of amyloid cardiomyopathy. Clin Nucl Med 10(3):156\u2013159. https:\/\/doi.org\/10.1097\/00003072-198503000-00004. Accessed 28 Jun 2021","DOI":"10.1097\/00003072-198503000-00004"},{"key":"10174_CR15","doi-asserted-by":"publisher","unstructured":"Janssen S, van Rijswijk MH, Piers DA, de Jong GM (1984) Soft-tissue uptake of 99mTc-diphosphonate in systemic AL amyloidosis. Eur J Nucl Med 9(12):538\u2013541.\u00a0https:\/\/doi.org\/10.1007\/BF00256851. Accessed 28 Jun\u00a02021","DOI":"10.1007\/BF00256851"},{"key":"10174_CR16","doi-asserted-by":"publisher","unstructured":"Braun SD, Lisbona R, Novales-Diaz JA, Sniderman A (1979) Myocardial uptake of 99mTc-phosphate tracer in amyloidosis. Clin Nucl Med\u00a04(6):244\u2013245.\u00a0https:\/\/doi.org\/10.1097\/00003072-197906000-00008. Accessed 16 Jun\u00a02021","DOI":"10.1097\/00003072-197906000-00008"},{"key":"10174_CR17","doi-asserted-by":"publisher","unstructured":"Falk RH, Lee VW, Rubinow A, Hood WB, Cohen AS (1983) Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 51(5):826\u2013830. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002914983801404. https:\/\/doi.org\/10.1016\/S0002-9149(83)80140-4. Accessed 16 Jun\u00a02021","DOI":"10.1016\/S0002-9149(83)80140-4"},{"key":"10174_CR18","doi-asserted-by":"publisher","unstructured":"Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM (1982) Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 103(4 Pt 1):468\u2013473.\u00a0https:\/\/doi.org\/10.1016\/0002-8703(82)90331-3. Accessed 16 Jun\u00a02021","DOI":"10.1016\/0002-8703(82)90331-3"},{"key":"10174_CR19","doi-asserted-by":"publisher","unstructured":"Schiff S, Bateman T, Moffatt R, Davidson R, Berman D (1982) Diagnostic considerations in cardiomyopathy: Unique scintigraphic pattern of diffuse biventricular technetium-99m-pyrophosphate uptake in amyloid heart disease. Am Heart J 103(4 Pt 1):562\u2013563.\u00a0https:\/\/doi.org\/10.1016\/0002-8703(82)90343-x. Accessed 16 Jun\u00a02021\u00a0","DOI":"10.1016\/0002-8703(82)90343-x"},{"issue":"6","key":"10174_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/archinte.1987.00370060035007","volume":"147","author":"MA Gertz","year":"1987","unstructured":"Gertz MA, Brown ML, Hauser MF, Kyle RA (1987) Utility of technetium tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 147(6):1039\u20131044.\u00a0https:\/\/doi.org\/10.1001\/archinte.1987.00370060035007. Accessed 16 Jun\u00a02021","journal-title":"Arch Intern Med"},{"key":"10174_CR21","doi-asserted-by":"publisher","unstructured":"Perugini E, Guidalotti PL, Salvi F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076\u20131084. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073. Accessed 8 Jun\u00a02021","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"10174_CR22","doi-asserted-by":"publisher","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195\u2013201. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.000132. Accessed 8 Jun\u00a02021","DOI":"10.1161\/CIRCIMAGING.112.000132"},{"key":"10174_CR23","doi-asserted-by":"publisher","unstructured":"Galat A, Rosso J, Guellich A et al (2015) Usefulness of (99m)tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 22(4):210\u2013220.\u00a0https:\/\/doi.org\/10.3109\/13506129.2015.1072089. Accessed 30 Jun\u00a02021","DOI":"10.3109\/13506129.2015.1072089"},{"key":"10174_CR24","doi-asserted-by":"publisher","unstructured":"Cappelli F, Gallini C, Di Mario C et al (2019) Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol 26(2):497\u2013504. https:\/\/doi.org\/10.1007\/s12350-017-0922-z. Accessed 30 Jun\u00a02021\u00a0","DOI":"10.1007\/s12350-017-0922-z"},{"key":"10174_CR25","doi-asserted-by":"publisher","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL et al (2011) Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 38(3):470\u2013478.\u00a0https:\/\/doi.org\/10.1007\/s00259-010-1642-7. Accessed 16 Jun\u00a02021","DOI":"10.1007\/s00259-010-1642-7"},{"key":"10174_CR26","doi-asserted-by":"publisher","unstructured":"Aljaroudi WA, Desai MY, Tang WHW, Phelan D, Cerqueira MD, Jaber WA (2014) Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 21(2):271\u2013283.\u00a0https:\/\/doi.org\/10.1007\/s12350-013-9800-5. Accessed 13 Jul\u00a02021\u00a0","DOI":"10.1007\/s12350-013-9800-5"},{"key":"10174_CR27","doi-asserted-by":"publisher","unstructured":"Bokhari S, Morgenstern R, Weinberg R et al (2018) Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol 25(1):181\u2013190.\u00a0https:\/\/doi.org\/10.1007\/s12350-016-0610-4. Accessed 29 Jun\u00a02021","DOI":"10.1007\/s12350-016-0610-4"},{"key":"10174_CR28","unstructured":"ASNC cardiac amyloidosis practice points. 99mTechnetium pyrophosphate imaging for transthyretin cardiac amyloidosis. https:\/\/www.asnc.org\/files\/19110%20ASNC%20Amyloid%20Practice%20Points%20WEB(2).pdf. Accessed 2 June 2021"},{"key":"10174_CR29","doi-asserted-by":"publisher","unstructured":"Dorbala S, Ando Y, Bokhari S et al (2020) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Nucl Cardiol 27(2):659\u2013673. https:\/\/doi.org\/10.1007\/s12350-019-01761-5. Accessed 2 Jun 2021","DOI":"10.1007\/s12350-019-01761-5"},{"key":"10174_CR30","unstructured":"ASNC Practice Points (2016) 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. https:\/\/www.asnc.org\/Files\/Practice%20Resources\/Practice%20Points\/ASNC%20Practice%20Point-99mTechnetiumPyrophosphateImaging2016.pdf. Accessed 2 Jun 2021"},{"key":"10174_CR31","doi-asserted-by":"publisher","unstructured":"Castano A, Haq M, Narotsky DL et al (2016) Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 1(8):880\u2013889.\u00a0https:\/\/doi.org\/10.1001\/jamacardio.2016.2839. Accessed 29 Jun\u00a02021","DOI":"10.1001\/jamacardio.2016.2839"},{"issue":"3","key":"10174_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13506129.2020.1744553","volume":"27","author":"MCA Coutinho","year":"2020","unstructured":"Coutinho MCA, Cortez-Dias N, Cantinho G et al (2020) The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid 27(3):174\u2013183.\u00a0https:\/\/doi.org\/10.1080\/13506129.2020.1744553. Accessed 17 Aug 2021","journal-title":"Amyloid"},{"key":"10174_CR33","doi-asserted-by":"publisher","unstructured":"Pilebro B, Suhr OB, N\u00e4slund U, Westermark P, Lindqvist P, Sundstr\u00f6m T (2016) (99m)tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 121(1):17\u201324.\u00a0https:\/\/doi.org\/10.3109\/03009734.2015.1122687. Accessed 17 Aug\u00a02021\u00a0","DOI":"10.3109\/03009734.2015.1122687"},{"key":"10174_CR34","doi-asserted-by":"publisher","unstructured":"Musumeci MB, Cappelli F, Russo D et al (2020) Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging 13(6):1314\u20131321.\u00a0https:\/\/doi.org\/10.1016\/j.jcmg.2019.10.015. Accessed\u00a017 Aug\u00a02021","DOI":"10.1016\/j.jcmg.2019.10.015"},{"key":"10174_CR35","doi-asserted-by":"publisher","unstructured":"Takasone K, Katoh N, Takahashi Y et al (2020) Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-pittsburgh compound B PET imaging. Amyloid 27(4):266\u2013274.\u00a0https:\/\/doi.org\/10.1080\/13506129.2020.1798223. Accessed 17 Aug 2021","DOI":"10.1080\/13506129.2020.1798223"},{"key":"10174_CR36","doi-asserted-by":"publisher","unstructured":"Pilebro B, Arvidsson S, Lindqvist P et al (2018) Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol 25(1):240\u2013248.\u00a0https:\/\/doi.org\/10.1007\/s12350-016-0638-5. Accessed 17 Aug\u00a02021\u00a0","DOI":"10.1007\/s12350-016-0638-5"},{"key":"10174_CR37","doi-asserted-by":"publisher","unstructured":"Hutt DF, Fontana M, Burniston M et al (2017) Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging 18(12):1344\u20131350. https:\/\/doi.org\/10.1093\/ehjci\/jew325. Accessed 6 Jul\u00a02021","DOI":"10.1093\/ehjci\/jew325"},{"key":"10174_CR38","doi-asserted-by":"publisher","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL et al (2011) Role of (99m)tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 4(6):659\u2013670.\u00a0https:\/\/doi.org\/10.1016\/j.jcmg.2011.03.016. Accessed 6 Jul 2021","DOI":"10.1016\/j.jcmg.2011.03.016"},{"key":"10174_CR39","doi-asserted-by":"publisher","unstructured":"Kristen AV, Haufe S, Schonland SO et al (2013) Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 164(2):179\u2013184.\u00a0https:\/\/doi.org\/10.1016\/j.ijcard.2011.06.123. Accessed 9 Jul\u00a02021","DOI":"10.1016\/j.ijcard.2011.06.123"},{"key":"10174_CR40","doi-asserted-by":"publisher","unstructured":"Vranian MN, Sperry BW, Hanna M et al (2018) Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes. J Nucl Cardiol 25(4):1247\u20131256. https:\/\/doi.org\/10.1007\/s12350-016-0768-9. Accessed 9 Jul 2021","DOI":"10.1007\/s12350-016-0768-9"},{"key":"10174_CR41","doi-asserted-by":"publisher","unstructured":"Sperry BW, Sato K, Phelan D et al (2019) Regional variability in longitudinal strain across vendors in patients with cardiomyopathy due to increased left ventricular wall thickness. Circ Cardiovasc Imaging 12(8):e008973.\u00a0https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.008973. Accessed 12 Jul\u00a02021","DOI":"10.1161\/CIRCIMAGING.119.008973"},{"key":"10174_CR42","doi-asserted-by":"publisher","unstructured":"Harb SC, Haq M, Flood K et al (2017) National patterns in imaging utilization for diagnosis of cardiac amyloidosis: a focus on Tc99m-pyrophosphate scintigraphy. J Nucl Cardiol 24(3):1094\u20131097. https:\/\/doi.org\/10.1007\/s12350-016-0478-3. Accessed 5 Jul\u00a02021","DOI":"10.1007\/s12350-016-0478-3"},{"key":"10174_CR43","doi-asserted-by":"publisher","unstructured":"Masri A, Bukhari S, Ahmad S et al (2020) Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging 13(2):e010249.\u00a0https:\/\/doi.org\/10.1161\/CIRCIMAGING.119.010249. Accessed 6 Jul\u00a02021\u00a0","DOI":"10.1161\/CIRCIMAGING.119.010249"},{"key":"10174_CR44","doi-asserted-by":"publisher","unstructured":"Sperry BW, Burgett E, Bybee KA et al (2020) Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT. J Nucl Cardiol 27(5):1802\u20131807. https:\/\/doi.org\/10.1007\/s12350-020-02139-8. Accessed 6 Jul\u00a02021\u00a0","DOI":"10.1007\/s12350-020-02139-8"},{"key":"10174_CR45","doi-asserted-by":"publisher","unstructured":"Santarelli MF, Genovesi D, Positano V et al (2020) Cardiac amyloidosis detection by early bisphosphonate (99mTc-HMDP) scintigraphy. J Nucl Cardiol.\u00a0https:\/\/doi.org\/10.1007\/s12350-020-02239-5. Accessed 12 Jul\u00a02021","DOI":"10.1007\/s12350-020-02239-5"},{"key":"10174_CR46","doi-asserted-by":"publisher","unstructured":"Galat A, Van der Gucht A, Guellich A et al (2017) Early phase 99Tc-HMDP scintigraphy for the diagnosis and typing of cardiac amyloidosis. JACC Cardiovasc Imaging 10(5):601\u2013603. https:\/\/doi.org\/10.1016\/j.jcmg.2016.05.007. Accessed 12 Jul\u00a02021\u00a0","DOI":"10.1016\/j.jcmg.2016.05.007"},{"key":"10174_CR47","doi-asserted-by":"publisher","unstructured":"Casta\u00f1o A, DeLuca A, Weinberg R et al (2016) Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol 23(6):1355\u20131363. https:\/\/doi.org\/10.1007\/s12350-015-0261-x. Accessed 6 Jul\u00a02021","DOI":"10.1007\/s12350-015-0261-x"},{"key":"10174_CR48","doi-asserted-by":"publisher","unstructured":"Casta\u00f1o A, Bokhari S, Maurer MS (2015) Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2595\u20132597.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehv328. Accessed 6 Jul\u00a02021\u00a0","DOI":"10.1093\/eurheartj\/ehv328"},{"key":"10174_CR49","doi-asserted-by":"publisher","unstructured":"Ramsay SC, Cuscaden C (2020) The current status of quantitative SPECT\/CT in the assessment of transthyretin cardiac amyloidosis. J Nucl Cardiol 27(5):1464\u20131468.\u00a0https:\/\/doi.org\/10.1007\/s12350-019-01935-1. Accessed 12 Jul\u00a02021","DOI":"10.1007\/s12350-019-01935-1"},{"key":"10174_CR50","doi-asserted-by":"publisher","unstructured":"Bailey DL, Willowson KP (2013) An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med 54(1):83\u201389.\u00a0https:\/\/doi.org\/10.2967\/jnumed.112.111476. Accessed 6 Jul\u00a02021\u00a0","DOI":"10.2967\/jnumed.112.111476"},{"issue":"3","key":"10174_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","volume":"25","author":"JC Ross","year":"2018","unstructured":"Ross JC, Hutt DF, Burniston M et al (2018) Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid 25(3):203\u2013210.\u00a0https:\/\/doi.org\/10.1080\/13506129.2018.1520087. Accessed 6 Jul 2021","journal-title":"Amyloid"},{"key":"10174_CR52","doi-asserted-by":"crossref","unstructured":"Scully PR, Morris E, Patel KP et al (2020) DPD quantification in cardiac amyloidosis: a novel imaging biomarker 13(6):1353\u20131363. https:\/\/qmro.qmul.ac.uk\/xmlui\/handle\/123456789\/65125","DOI":"10.1016\/j.jcmg.2020.03.020"},{"key":"10174_CR53","doi-asserted-by":"publisher","unstructured":"Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ (2020) Quantitative 99mTc-DPD SPECT\/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol\u00a027(5):1456\u20131463.\u00a0https:\/\/doi.org\/10.1007\/s12350-019-01893-8. Accessed 6 Jul\u00a02021","DOI":"10.1007\/s12350-019-01893-8"},{"key":"10174_CR54","doi-asserted-by":"publisher","unstructured":"Ramsay SC, Lindsay K, Fong W, Patford S, Younger J, Atherton J (2018) Tc-HDP quantitative SPECT\/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging 2(1):17. https:\/\/doi.org\/10.1186\/s41824-018-0035-1. Accessed 6 Jul 2021","DOI":"10.1186\/s41824-018-0035-1"},{"key":"10174_CR55","doi-asserted-by":"publisher","unstructured":"Dorbala S, Park M, Cuddy S et al (2021) Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT. J Nucl Med 62(5):716\u2013722. https:\/\/doi.org\/10.2967\/jnumed.120.247312. Accessed 7 Jul\u00a02021\u00a0","DOI":"10.2967\/jnumed.120.247312"},{"key":"10174_CR56","doi-asserted-by":"publisher","unstructured":"Bellevre D, Bailliez A, Delelis F et al (2020) Quantitation of myocardial 99mTc-HMDP uptake with new SPECT\/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: ready for clinical use? J Nucl Cardiol.\u00a0https:\/\/doi.org\/10.1007\/s12350-020-02274-2. Accessed 12 Jul 2021","DOI":"10.1007\/s12350-020-02274-2"},{"issue":"1","key":"10174_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40336-018-0264-0","volume":"6","author":"BF Hutton","year":"2018","unstructured":"Hutton BF, Erlandsson K, Thielemans K (2018) Advances in clinical molecular imaging instrumentation. Clinical and Translational Imaging 6(1):31\u201345.\u00a0https:\/\/doi.org\/10.1007\/s40336-018-0264-0.","journal-title":"Clinical and Translational Imaging"},{"key":"10174_CR58","doi-asserted-by":"publisher","unstructured":"Dorbala S, Kijewski MF, Park M (2020) Quantitative bone-avid tracer SPECT\/CT for cardiac amyloidosis: A crucial step forward. JACC Cardiovasc Imaging 13(6):1364\u20131367. https:\/\/doi.org\/10.1016\/j.jcmg.2020.05.005. Accessed 26 Jun 2021","DOI":"10.1016\/j.jcmg.2020.05.005"},{"key":"10174_CR59","doi-asserted-by":"publisher","unstructured":"Kudo T, Imakhanova A (2020) Quantification of amyloid deposition using bone scan agents. J Nucl Cardiol.\u00a0https:\/\/doi.org\/10.1007\/s12350-020-02340-9. Accessed 23 Jul\u00a02021\u00a0","DOI":"10.1007\/s12350-020-02340-9"},{"key":"10174_CR60","doi-asserted-by":"publisher","unstructured":"Tamarappoo B, Otaki Y, Manabe O et al (2020) Simultaneous tc-99m PYP\/tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol 27(1):28\u201337. https:\/\/doi.org\/10.1007\/s12350-019-01753-5. Accessed 8 Jul\u00a02021","DOI":"10.1007\/s12350-019-01753-5"},{"key":"10174_CR61","doi-asserted-by":"publisher","unstructured":"Cuddy S, Dorbala S, Di Carli MF (2020) Imaging of cardiac amyloidosis: will this become a unique application for dual-isotope imaging? J Nucl Cardiol 27(1):38\u201340.\u00a0https:\/\/doi.org\/10.1007\/s12350-019-01754-4. Accessed 8 Jul\u00a02021\u00a0","DOI":"10.1007\/s12350-019-01754-4"},{"issue":"1","key":"10174_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1716793. Accessed 21 Jun 2021","journal-title":"N Engl J Med"},{"key":"10174_CR63","doi-asserted-by":"publisher","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1716153. Accessed 21 Jun\u00a02021\u00a0","DOI":"10.1056\/NEJMoa1716153"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10174-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10174-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10174-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T07:29:33Z","timestamp":1660807773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10174-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10174"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10174-x","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"assertion":[{"value":"16 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}